Vnitr Lek 2010, 56(10):1058-1064

Past, present and future of obesity pharmacotherapy

Ľ. Fábryová
Metabol KLINIK s.r.o., Ambulancia pre diabetológiu, poruchy látkovej premeny a výživy, Bratislava, Slovenská republika, vedúci lekár MUDr. Ľubomíra Fábryová, PhD.

Obese (BMI ≥ 30 kg/m2) and overweight (BMI ≥ 25 and < 30 kg/m2) individuals are at high risk of developing serious chronic health problems, including type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease. Caloric restriction, increased physical activity and behavioral therapy remain the primary treatment options for the management of body weight in these individuals. When a weight loss of 5-10% cannot be achieved in 3-6 months by lifestyle changes drug therapy might be indicated. This review will provide a brief history of obesity pharmacotherapy, discuss the status of currently available obesity drugs and outline the future drug development. A medical need exists for the development of novel weight loss therapies or combinations of known therapies.

Keywords: obesity; pharmacotherapy; orlistat; combination therapy; new antiobesitics

Received: July 12, 2010; Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fábryová Ľ. Past, present and future of obesity pharmacotherapy. Vnitr Lek. 2010;56(10):1058-1064.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. World Health Organization. Obesity and overweight. Fact Sheet No. 311. September 2006. Available from: http://www.who.intlmediacentre/factsheets/fs311/en/index.html.
    2. Aronne LJ, Nelinson DS, Lillo JL et al. Obesity as a disease state: a new paradigm for diagnosis and treatment. Clin Cornerstone 2009; 9: 9-29. Go to original source... Go to PubMed...
    3. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589. Go to original source... Go to PubMed...
    4. Tsigos K, Hainer V, Basdevant A et al. Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1: 106-116. Go to original source... Go to PubMed...
    5. Tsigos C, Hainer V, Basdevant A et al. Obesity Management Task Force Európskej obezitologickej spoločnosti (European Association for the Study of Obesity) Liečba obezity u dospelých: Európske odporúčania pre klinickú prax. Diabetes a obezita 2009; 17: 10-20.
    6. Fried M, Hainer V, Basdevant A et al. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Obes Surg 2007; 17: 260-270. Go to original source... Go to PubMed...
    7. Fried M, Hainer V, Basdevant A et al. Interdisciplinárne európske odporúčania pre chirurgickú liečbu ťažkej obezity. Diabetes a obezita 2009; 17: 22-28.
    8. Weigle DS. Pharmacological therapy of obesity: past, present and future. J Clin Endocrinol Metab 2003; 88: 2462-2469. Go to original source... Go to PubMed...
    9. Council on Pharmacy and Chemistry 1935. Dinitrophenol not acceptable for N. N. R. JAMA 1935; 105: 31-33. Go to original source...
    10. Smith HJ, Roche AH, Jausch MF et al. Cardiomyopathy associated with amphetamine administration. Am Heart J 1976; 91: 792-797. Go to original source... Go to PubMed...
    11. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa 1985; 27: 160-171.
    12. Mark EJ, Patalas ED, Chang HT et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337: 602-606. Go to original source... Go to PubMed...
    13. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588. Go to original source... Go to PubMed...
    14. Addy C, Jumes P, Rosko K et al. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. J Clin Pharmacol 2009; 49: 1228-1238. Go to original source... Go to PubMed...
    15. Morgenstern LB, Wilterdink JL, Horwitz RI. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826-1832. Go to original source... Go to PubMed...
    16. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833-1838. Go to original source... Go to PubMed...
    17. Payer J, Hainer V, Ondrejka P et al. Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study). Vnitř Lék 2004; 50: 825-829. Go to PubMed...
    18. James WP. The SCOUT study: risk-benefit profile of sibutramine in overweight high risk cardiovascular patients. Eur Heart J Suppl 2005; 7 (Suppl L): L44-L48. Go to original source...
    19. Torp-Pedersen C, Caterson I, Coutinho W et al. SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915-2923. Go to original source... Go to PubMed...
    20. Weeke P, Andersson C, Fosbøl EL et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period. BMC Endocr Disord 2010; 10: 3. Go to original source... Go to PubMed...
    21. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. Eur Heart J 2005; 7 (Suppl L): L32-L38. Go to original source...
    22. McClendon K, Riche DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf 2009; 8: 724-744. Go to original source... Go to PubMed...
    23. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161. Go to original source... Go to PubMed...
    24. Sjöström L. Analysis of the XENDOS study (Xenical in the prevention of diabetes in obese subjects). Endocr Pract 2006; 12 (Suppl 1): 31-33. Go to original source... Go to PubMed...
    25. Rössner S, Sjöström L, Noack R et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49-61. Go to original source... Go to PubMed...
    26. Bray GA. Medications for weight reduction. Endocrinol Metab Clin North Am 2008; 37: 923-942. Go to original source... Go to PubMed...
    27. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 2007; 369: 71-77. Go to original source... Go to PubMed...
    28. Wadden TA, Berkowitz RI, Womble LG et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8: 431-437. Go to original source... Go to PubMed...
    29. Smith SR, Prosser WA, Donahue DJ et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity 2009; 17: 494-503. Go to original source... Go to PubMed...
    30. Akbas F, Gasteyger A, Sjödin A et al. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 2009; 10: 58-67. Go to original source... Go to PubMed...
    31. Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother 2009; 10: 921-925. Go to original source... Go to PubMed...
    32. Adis Data Information BV. Naltrexone/Bupropion Contrave; Naltrexone SR/Bupropion SR. Drugs RD 2010; 10: 25-32. Go to original source... Go to PubMed...
    33. Kopelman P, Bryson A, Hickling R et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007; 31: 494-499. Go to original source... Go to PubMed...
    34. Siddiqui NI. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh Med J 2009; 18: 113-124. Go to PubMed...
    35. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007; 99: 68B-79B. Go to original source... Go to PubMed...
    36. Svačina Š. Léčba obezity u metabolického syndromu. Vnitř Lék 2009; 55: 622-625. Go to PubMed...
    37. Bhushan R, Elkind-Hirsch KE, Bhushan M et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr pract 2008; 14: 993-999. Go to original source... Go to PubMed...
    38. Moran TH, Dailey MJ. Minireview: Gut peptides: targets for antiobesity drug development? Endocrinology 2009; 150: 2526-2530. Go to original source... Go to PubMed...
    39. Ravussin E, Smith SR, Mitchell JA. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009; 17: 1736-1743. Go to original source... Go to PubMed...
    40. Smith SR, Aronne LJ, Burns CM et al. Sustained weight loss following 12-months pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31: 1816-1823. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.